Roivant Sciences Shares Rise on Positive Mosliciguat Trial Results
Roivant Sciences (ROIV) experienced an almost 19% increase in its stock price following positive results from a mid-stage clinical trial for its pulmonary hypertension candidate, mosliciguat. The drug met the primary endpoint of the study, which contributed to investor optimism and strong market performance on Tuesday. The company closed at $41.48 per share after gaining $6.55 compared to the previous day's close. This significant rise reflects positive sentiment among investors regarding Roivant’s progress in developing treatments for pulmonary hypertension, a condition affecting blood pressure in arteries of the lungs and right side of the heart. The trial results are seen as an important milestone that could potentially accelerate mosliciguat toward later-stage development or regulatory approval.
Tickers: $ROIV
Topics: biopharmaceutical pulmonary_hypertension stock_movement